KU-55933: Potent and Selective ATM Kinase Inhibitor for DNA Damage Response Research

Executive Summary: KU-55933 is a highly selective ATM kinase inhibitor with an IC₅₀ of 13 nM and Ki of 2.2 nM, demonstrating robust selectivity over DNA-PK, PI3K/PI4K, ATR, and mTOR (Hickson 2004, DOI). It is widely employed to dissect ATM-mediated DNA damage checkpoint signaling and to study the inhibition of Akt phosphorylation at Ser473, which is crucial for cell survival (Golding 2009, DOI). Cellular assays confirm that KU-55933 suppresses proliferation and induces G1 cell cycle arrest in multiple cancer cell lines (Zhang 2011, DOI). Metabolic modulation by KU-55933 includes increased lactate production and glucose consumption, with decreased ATP in MCF-7 cells (Bao 2009, DOI). The compound, supplied by APExBIO (SKU: A4605), is recommended for research applications in DNA repair, apoptosis, and cell cycle studies (product page).

Biological Rationale

The ataxia-telangiectasia mutated (ATM) kinase is a central regulator of the DNA damage response (DDR) pathway. Upon detection of DNA double-strand breaks (DSBs), ATM phosphorylates key substrates involved in cell cycle checkpoints, DNA repair, and apoptosis, such as p53, CHK2, and H2AX (Zhen et al., 2023). Disruption of ATM function leads to impaired DSB repair, genomic instability, and increased cancer susceptibility, as observed in ataxia-telangiectasia patients. Inhibition of ATM activity is a strategic approach to sensitize cancer cells to DNA-damaging therapies and to probe the mechanisms underlying genome maintenance. KU-55933 is a small molecule inhibitor that enables precise, reversible, and dose-dependent modulation of ATM function in vitro and in cell-based systems. Its high selectivity allows researchers to distinguish ATM-dependent signaling from other phosphoinositide 3-kinase-related kinases (PIKKs).

Mechanism of Action of KU-55933 (ATM Kinase Inhibitor)

KU-55933 competitively binds to the ATP-binding site of ATM kinase, resulting in potent inhibition of its catalytic activity. The inhibitor exhibits an IC₅₀ of 13 nM and a Ki of 2.2 nM for ATM, with >100-fold selectivity over DNA-PK, PI3K, PI4K, ATR, and mTOR, minimizing off-target effects (Hickson 2004). ATM inhibition by KU-55933 prevents phosphorylation of downstream effectors, notably Akt at Ser473, which is vital for cell survival and proliferation pathways (Golding 2009, DOI). This suppression disrupts the cellular response to DNA damage, leading to G1 cell cycle arrest via downregulation of cyclin D1 and impaired checkpoint activation. Additionally, ATM inhibition modulates cellular metabolism, as shown by increased lactate output and glucose uptake accompanied by reduced ATP levels in breast cancer cells (Bao 2009, DOI).

Evidence & Benchmarks

• KU-55933 inhibits ATM kinase with an IC₅₀ of 13 nM and a Ki of 2.2 nM under in vitro kinase assay conditions (Hickson 2004, DOI).
• Demonstrates >100-fold selectivity for ATM over DNA-PK, PI3K, PI4K, ATR, and mTOR in comparative kinase panels (Hickson 2004, DOI).
• Suppresses Akt phosphorylation at Ser473 following DNA damage, linking ATM to survival signaling (Golding 2009, DOI).
• Induces approximately 50% inhibition of proliferation at 10 μM in MDA-MB-453 and PC-3 cancer cell lines following 48-hour treatment at 37°C (Zhang 2011, DOI).
• Alters metabolism: increased lactate production (+25%), glucose consumption (+30%), and reduced ATP levels (−20%) in MCF-7 cells after 24 hours (Bao 2009, DOI).
• Induces G1 cell cycle arrest through downregulation of cyclin D1 in human cancer cell lines (Zhang 2011, DOI).
• Promotes radiosensitization in p53-deficient tumor cells by impairing DNA DSB repair pathways (Golding 2009, DOI).

This article extends previous overviews such as "KU-55933: Potent and Selective ATM Kinase Inhibitor for DDR" by providing updated benchmarks and new application insights relevant for translational research.

Applications, Limits & Misconceptions

KU-55933 is extensively utilized in cancer research to investigate ATM-dependent DNA damage checkpoint signaling, cell cycle regulation, apoptosis, and metabolic reprogramming. It serves as a sensitizer in preclinical models for radiotherapy and chemotherapeutic regimens targeting p53-deficient malignancies. Its high selectivity profile allows for mechanistic dissection of ATM signaling without perturbing related PIKK family members. Researchers also employ KU-55933 to elucidate the interplay between ATM and nuclear cGAS in the context of genome integrity and retrotransposon repression, as highlighted by recent studies (Zhen et al., 2023).

For advanced, scenario-driven deployment of KU-55933 in DNA damage response and proliferation assays, see "KU-55933 (ATM Kinase Inhibitor): Scenario-Based Strategies", which this article updates by integrating new metabolic and checkpoint data.

Common Pitfalls or Misconceptions

• Not selective for ATR or DNA-PK: KU-55933 does not significantly inhibit ATR or DNA-PK at concentrations ≤10 μM; results cannot be extrapolated to these kinases (Hickson 2004).
• Solubility constraints: KU-55933 is insoluble in water and ethanol; DMSO (≥41.67 mg/mL) with gentle warming is required for proper dissolution (APExBIO).
• Not suitable for long-term solution storage: Solutions degrade over time; fresh preparation is advised for reproducible results (product documentation).
• Does not induce DNA damage: KU-55933 is an inhibitor of ATM signaling, not a DNA-damaging agent; it must be paired with genotoxic stressors for DDR studies.
• Cell line-specific effects: Sensitivity and G1 arrest may vary across cell types; benchmark in your model system before interpretation (Zhang 2011).

This guide also clarifies workflow integration beyond what is covered in "Optimizing Cell-Based Assays with KU-55933" by emphasizing compound handling, solubility, and storage details for reproducibility.

Workflow Integration & Parameters

• Stock Preparation: Dissolve KU-55933 (solid) in DMSO to make a stock solution (≥41.67 mg/mL). Gentle warming may be applied. Avoid water or ethanol (APExBIO).
• Storage: Store solid compound desiccated at −20°C. Stock solutions can be kept at −20°C for several months but should be used promptly after thawing.
• Working Concentration: Typical in vitro and cellular assay concentrations range from 0.1 μM to 10 μM. Titrate for cell-type and endpoint optimization.
• Controls: Always include DMSO-only and DNA damage (e.g., irradiation, etoposide) controls in experimental design.
• Readouts: Assess ATM inhibition by monitoring phosphorylation status of ATM targets (e.g., p-Ser1981 ATM, p-Ser473 Akt, γ-H2AX) using Western blot or flow cytometry.
• Cellular Contexts: KU-55933 is validated in breast (MCF-7, MDA-MB-453), prostate (PC-3), and other cancer cell lines; confirm effects in your specific model system.

Conclusion & Outlook

KU-55933, available from APExBIO, is a gold-standard tool for inhibition of ATM-mediated signaling in DNA damage response research (KU-55933 (ATM Kinase Inhibitor)). Its nanomolar potency, selectivity, and broad application across cell cycle, metabolism, and genome stability studies make it indispensable for probing DDR pathways and developing cancer therapeutics. Ongoing research explores its integration with emerging insights on nuclear cGAS and retrotransposon control, as discussed in "ATM Kinase Inhibition Reimagined: Strategic Insights", which this guide augments by providing actionable parameters and updated mechanistic context. For reproducibility, adhere to documented compound handling and experimental controls. As new ATM-dependent regulatory axes are discovered, KU-55933 remains a critical reagent for mechanistic and translational research in genome maintenance and cancer biology.